• Luye Pharma launched a USD 180 million offering of 5.25% convertible bonds due 2031, with settlement set for June 10, 2026.
• Proceeds expected at about USD 177.2 million net, earmarked to refinance debt, including funding a concurrent repurchase of its 6.25% convertible bonds due 2028.
• The company has commitments to repurchase about USD 89.74 million of the 2028 convertible bonds at USD 1,031.25 per USD 1,000 principal.
• Initial conversion price set at HKD 2.71 per share, implying up to 520,498,892 shares on full conversion, about 13.03% of current issued capital.
• The bonds are intended to be listed on the Vienna Stock Exchange, with conversion shares to be listed in Hong Kong.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260604-12188351), on June 03, 2026, and is solely responsible for the information contained therein.